The Revolutionary Synthesis of Cancer-Fighting Compound Verticillin A
The discovery of the fungal compound verticillin A over 50 years ago sparked interest in its potential cancer-fighting properties. Scientists have now achieved a significant milestone by successfully synthesizing this compound in the lab for the first time, opening up new avenues for research and the development of novel cancer treatments.
Producing verticillin A in the laboratory represents a major breakthrough, as the compound is naturally found in minuscule amounts in a microscopic fungus and is notoriously challenging to extract.
Prior to this achievement, the complex chemical structure and instability of verticillin A posed obstacles to its synthesis. However, researchers from MIT and Harvard Medical School have overcome these hurdles.
The key to this success was adapting a method previously used by MIT chemist Mohammad Movassaghi to synthesize similar compounds with slight structural differences from verticillin A.
“We have a much better appreciation for how those subtle structural changes can significantly increase the synthetic challenge,” Movassaghi explains. “Now we can not only access verticillin A for the first time in more than 50 years, but also create designed variants for further studies.”
Verticillin A comprises two identical halves fused together to form a dimer molecule. Despite its seemingly simple structure, precise arrangement is crucial for the compound to take shape in three dimensions.
The researchers employed strategic techniques such as modifying the sequence of molecule addition and safeguarding delicate bonds during synthesis to construct verticillin A through a 16-step process. This approach allowed them to achieve the desired 3D structure of the compound.
“What we learned was the timing of the events is absolutely critical,” Movassaghi emphasizes. “We had to significantly change the order of the bond-forming events.”
In laboratory experiments on diffuse midline glioma (DMG) cells, a type of aggressive brain cancer affecting children, the synthetic verticillin A and its derivatives exhibited promising results in killing cancer cells. Furthermore, the new compound was found to effectively target specific proteins within the cells.
With the successful synthesis of verticillin A, researchers now have the opportunity to delve deeper into its interactions with cancer cells and explore its potential for therapeutic applications.
“Natural compounds have been invaluable in drug discovery, and we will fully assess the therapeutic potential of these molecules by combining our expertise in chemistry, chemical biology, cancer biology, and patient care,” says chemical biologist Jun Qi from Harvard Medical School.
The groundbreaking research has been published in the Journal of the American Chemical Society.
